Hemodialysis Clinical Trial
Official title:
A Prospective Multicenter, Open Label, Non-Randomized, Cross-Over Study Evaluating the Use of the DIMI Renal Replacement Therapy (RRT) System In-Center by Trained Dialysis Nurses and In-Home by Trained Care Partners and Patients With End Stage Renal Disease (ESRD) Who Are on Stable Dialysis Regimens.
NCT number | NCT04868643 |
Other study ID # | DIAL-DIMI-001 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | January 2023 |
Est. completion date | August 2026 |
Verified date | March 2024 |
Source | Dialco Medical Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a prospective, multicenter, open label, non-randomized, cross-over study. Subjects will be enrolled in the trial for approximately 18 weeks and will use the DIMI RRT System for their dialysis treatments for all study phases, according to the schedule outlined below. The schedule will consist of four phases and the number of sessions per week will be prescribed the same throughout Phase 1 to 4.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | August 2026 |
Est. primary completion date | August 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Subject has provided informed consent and has signed a Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant authorization statement. 2. Subject is at least 18 years and less than 75 years of age. 3. Subject has identified an individual "Care Partner" to be trained and available as needed. Such Care Partner must be considered competent to train on the use of the device by the prescribing physician, and must commit to the trial. 4. Subject has end stage renal disease (ESRD) adequately treated by maintenance dialysis achieving a Kt/V = 1.2 and has been deemed stable for at least three months by his/her treating nephrologist. 5. Subject has a well-functioning and stable vascular access that allows a blood flow of at least 300 ml/min. 6. Subject has a documented psychosocial evaluation by a qualified social worker, treating physician or home hemodialysis nurse. 7. Subject has no childbearing potential or has a negative pregnancy test within 7 days prior to the start of the first study treatment and will be utilizing medically acceptable means of contraception during the study period. 8. Subject has a home environment to perform hemodialysis that meets the criteria of Home Use Environment (defined in Section 15.1). Exclusion Criteria: 1. Subject has dementia or lacks capacity for self-care. 2. Life expectancy less than 12 months from first study procedure. 3. Subject is unable to understand or cooperate with hemodialysis nurse and dialysis care team. 4. Subject has a documented history of non-adherence to dialysis treatment that would prevent successful completion of the study. 5. Subject has had a recent major cardiovascular adverse event within the last 3 months. 6. Subject has New York Class III or IV Congestive Heart Failure, or ejection fraction less than 30%. 7. Subject has a persistent pre-dialysis sitting systolic blood pressure less than 100 mmHg despite medical therapy. 8. Subject has symptomatic intra-dialytic hypotension requiring medical intervention in two of their last three treatments. 9. Subject has an active infection requiring antibiotics within the last 7 days. 10. Subject has fluid overload due to intractable ascites secondary to liver cirrhosis. 11. Subject has uncontrolled blood pressure (e.g. sustained/persistent pre- dialysis systolic blood pressure greater than 180 mmHg despite maximal medical therapy in two of the last three treatments). 12. Subject is intolerant to heparin. 13. Subject is seroreactive for Hepatitis B Surface Antigen. 14. Subject has an active, life-threatening, rheumatologic disease. 15. Subject has a history of adverse reactions to dialyzer membrane material. 16. Subject is participating in another investigative drug or device clinical study related to Home Hemodialysis which conflicts with the execution of this study. 17. Subject is expected to receive a kidney transplant from any donor organ in the next 6 months. 18. Subject has a life-threatening malignancy actively receiving treatment that would prevent successful completion of the study protocol. 19. Any other condition that the Investigator feels would prevent the Subject from being a suitable candidate for inclusion in the study. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Dialco Medical Inc. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Delivery of the prescribed fluid volume, defined as delivered volume that is at least 90% of prescribed volume at each in-home dialysis session. | The delivered volume is the total effluent volume (spent dialysate plus net ultrafiltrate) as measured by the device by means of 2 independent and calibrated electronic scales. The effluent volume is an effective means of assessing the usability of the machine in different environments and by different people, as any early interruption of treatment will result in a lower delivered volume. | 6 weeks | |
Secondary | Delivery of a standardized weekly Kt/V based on lab data. | The secondary efficacy endpoint is the delivery of a standardized weekly Kt/V of greater than or equal to 2.1, that will be measured weekly. The standardized weekly Kt/V value will be computed by the Sponsor and included in the study database from laboratory data provided and recorded by the site via the Case Report Forms (CRFs). | 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04892745 -
Impact of Hemodialysis on Cutaneo-muscular Electrical Impedance
|
||
Not yet recruiting |
NCT04925674 -
Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis.
|
Phase 1 | |
Active, not recruiting |
NCT03183245 -
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
|
Phase 3 | |
Completed |
NCT03365635 -
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
|
Phase 4 | |
Withdrawn |
NCT02904343 -
Evaluation of Domestic Hemodialysis Machine: A Multi-center Clinical Study
|
N/A | |
Withdrawn |
NCT01855334 -
L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD
|
Phase 4 | |
Completed |
NCT01700465 -
Estimating and Predicting Hemodynamic Changes During Hemodialysis
|
N/A | |
Recruiting |
NCT01195519 -
The Assessment of Quality of Life in Patients With Peritoneal Dialysis and Hemodialysis
|
N/A | |
Completed |
NCT00737672 -
GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis
|
Phase 3 | |
Completed |
NCT00527774 -
Effect of HCV Infection on Insulin Resistance and Malnutrition-inflammation Complex Syndrome in Regular Hemodialysis Patients
|
N/A | |
Completed |
NCT00942253 -
Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)
|
Phase 2 | |
Completed |
NCT00224081 -
DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)
|
Phase 4 | |
Completed |
NCT00850252 -
Use of a Lifeline Graft in the A-V Shunt Model
|
Phase 1/Phase 2 | |
Completed |
NCT00776750 -
Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients
|
Phase 4 | |
Recruiting |
NCT06351007 -
Educational Program on Dietary Adherence and Nutritional Knowledge in Chronic Kidney Disease Patients (EPAK)
|
N/A | |
Withdrawn |
NCT03664141 -
Impact of Cannabis Oil on Nutrition in Hemodialysis Patients Study (ICON-HP Study)
|
Phase 3 | |
Completed |
NCT03909698 -
Antibiotic Dosing in Patients on Intermittent Hemodialysis
|
||
Recruiting |
NCT03311321 -
Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients
|
N/A | |
Recruiting |
NCT06098924 -
HD Patients' Depression and Happiness
|
||
Recruiting |
NCT03419923 -
Three Anticoagulation Strategies for Hemodialysis in Patients at Risk of Hemorrhage
|
N/A |